GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Price-to-Free-Cash-Flow

PCRX (Pacira BioSciences) Price-to-Free-Cash-Flow : 6.98 (As of May. 13, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Price-to-Free-Cash-Flow?

As of today (2025-05-13), Pacira BioSciences's share price is $23.40. Pacira BioSciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $3.35. Hence, Pacira BioSciences's Price-to-Free-Cash-Flow Ratio for today is 6.98.

The historical rank and industry rank for Pacira BioSciences's Price-to-Free-Cash-Flow or its related term are showing as below:

PCRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.48   Med: 31.18   Max: 625.12
Current: 6.99

During the past 13 years, Pacira BioSciences's highest Price-to-Free-Cash-Flow Ratio was 625.12. The lowest was 3.48. And the median was 31.18.

PCRX's Price-to-Free-Cash-Flow is ranked better than
88.78% of 508 companies
in the Drug Manufacturers industry
Industry Median: 23.19 vs PCRX: 6.99

Pacira BioSciences's Free Cash Flow per Share for the three months ended in Mar. 2025 was $0.58. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $3.35.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Pacira BioSciences was 7.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 30.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 27.60% per year.

During the past 13 years, Pacira BioSciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 83.60% per year. The lowest was 2.80% per year. And the median was 44.00% per year.


Pacira BioSciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Pacira BioSciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Price-to-Free-Cash-Flow Chart

Pacira BioSciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.64 34.38 15.60 12.57 4.87

Pacira BioSciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.40 8.51 4.12 4.87 7.41

Competitive Comparison of Pacira BioSciences's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Price-to-Free-Cash-Flow falls into.


;
;

Pacira BioSciences Price-to-Free-Cash-Flow Calculation

Pacira BioSciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=23.40/3.352
=6.98

Pacira BioSciences's Share Price of today is $23.40.
Pacira BioSciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Pacira BioSciences  (NAS:PCRX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Pacira BioSciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Executives
Jonathan Slonin officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Daryl Gaugler officer: Chief Operating Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Marcelo Bigal director C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark Froimson director 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Kristen Marie Williams officer: CAO and General Counsel C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Lauren Bullaro Riker officer: Executive Director, Accounting C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Abraham Ceesay director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Roy Winston officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Mark A. Kronenfeld director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Reinhart Charles A. Iii officer: Chief Financial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054

Pacira BioSciences Headlines

From GuruFocus